Patents by Inventor Matthew A. TIRRELL

Matthew A. TIRRELL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240052330
    Abstract: The disclosure is directed to methods of inhibiting coronavirus infection using a hydrocarbon stapled peptide which is a peptidomimetic of the human angiotensin-converting enzyme 2 (hACE2). The hydrocarbon stapled peptide binds to the receptor binding domain (RBD) of a coronavirus spike protein (S) and inhibits binding of the coronavirus to hACE2 expressed on the surface of host cells.
    Type: Application
    Filed: December 22, 2021
    Publication date: February 15, 2024
    Inventors: Yu TIAN, Sicheng JIANG, Jeffrey A. HUBBELL, Matthew A. TIRRELL, James L. LABELLE
  • Publication number: 20240033373
    Abstract: Provided herein are nanoparticles to encapsulate therapeutic agents and methods of use thereof for intracellular delivery and disease treatment. In particular, the present disclosure provides polymersomes for use in the delivery of therapeutic agents, e.g. stapled peptides, to diseased (e.g. cancer) cells.
    Type: Application
    Filed: August 31, 2021
    Publication date: February 1, 2024
    Inventors: Matthew Tirrell, James L. Labelle, Mathew Schnorenberg, Jeffrey A. Hubbell, Elyse A. Watkins
  • Publication number: 20230285446
    Abstract: The disclosure provides products and methods of treating diseases and disorders involving microbial pathogens, such as intestinal microbial pathogens, e.g., Pseudomonas aeruginosa, by administering an effective amount of a phosphorylated polyethylene glycol compound of defined structural organization. Those diseases and disorders characterized by an epithelium attacked by a microbial pathogen are contemplated, including gastrointestinal infections and inflammation, e.g., treatment of intestinal or esophageal anastomosis or treatment or suppression of anastomotic leakage.
    Type: Application
    Filed: January 18, 2023
    Publication date: September 14, 2023
    Applicants: The University of Chicago, UChicago Argonne, LLC
    Inventors: John C. Alverdy, Matthew Tirrell, Olga Y. Zaborina, Jun Mao, Wei Chen
  • Patent number: 11571443
    Abstract: The disclosure provides products and methods of treating diseases and disorders involving microbial pathogens, such as intestinal microbial pathogens, e.g., Pseudomonas aeruginosa, by administering an effective amount of a phosphorylated polyethylene glycol compound of defined structural organization. Those diseases and disorders characterized by an epithelium attacked by a microbial pathogen are contemplated, including gastrointestinal infections and inflammation, e.g., treatment of intestinal or esophageal anastomosis or treatment or suppression of anastomotic leakage.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 7, 2023
    Assignee: The University of Chicago
    Inventors: John C. Alverdy, Matthew Tirrell, Olga Y. Zaborina, Jun Mao, Wei Chen
  • Publication number: 20220216321
    Abstract: Redox gating, intrinsically apart from conventional electrolyte gating, combines reversible redox functionalities with common ionic electrolyte moieties to engineer charge transport for power efficient phase control. A colossal sheet carrier density modulation beyond 1016/cm2 as well as up to thousand durable cycling can be reached at the subvolt regime in archetypical functional oxide thin films without unbridled perturbations from ionic defects, which include either cation/anion vacancy or ionic intercalated species like proton. Besides, the redox gating represents a simply and practical way to decouple the electrical and structural phase transitions, improving the device longevity and operation response time. The redox gating works for a wide variety of materials regardless of its crystallinity or crystallographic orientation, including all other functional heterostructures and low-dimensional quantum materials composed of sustainable elements.
    Type: Application
    Filed: January 4, 2021
    Publication date: July 7, 2022
    Inventors: Wei Chen, Matthew Tirrell, Hua Zhou, Le Zhang, Hui Cao, Changjiang Liu
  • Publication number: 20190247423
    Abstract: The disclosure provides products and methods of treating diseases and disorders involving microbial pathogens, such as intestinal microbial pathogens, e.g., Pseudomonas aeruginosa, by administering an effective amount of a phosphorylated polyethylene glycol compound of defined structural organization. Those diseases and disorders characterized by an epithelium attacked by a microbial pathogen are contemplated, including gastrointestinal infections and inflammation, e.g., treatment of intestinal or esophageal anastomosis or treatment or suppression of anastomotic leakage.
    Type: Application
    Filed: September 29, 2017
    Publication date: August 15, 2019
    Inventors: John C. Alverdy, Matthew Tirrell, Olga Y. Zaborina, Jun Mao, Wei Chen
  • Publication number: 20190054012
    Abstract: Provided herein are polymer-stabilized CaP nanoparticle formulations and related methods of manufacture. In certain embodiments, the methods reliably and selectively form nanoparticles with homogenous size, charge, and morphology. The CaP nanoparticles include calcium ions and phosphate ions with an ionic polymer, thereby forming stable hybrid nanoparticles. The CaP nanoparticle formulations include powders, suspensions and injectable pastes. According to various embodiments, the polymer-stabilized CaP nanoparticles may be polycation-stabilized (CaP/polymer(+) nanoparticles) or polyanion-stabilized (CaP/polymer(-) nanoparticles). The CaP/polymer nanoparticles can be freeze-dried and stored for months with no loss of properties or changes to their morphology.
    Type: Application
    Filed: March 13, 2017
    Publication date: February 21, 2019
    Inventors: Juan Jose de Pablo, Nader Taheri Qazvini, Monirosadat Sadati, Matthew Tirrell
  • Publication number: 20180066031
    Abstract: Provided herein are enzymatically-cleavable peptide amphiphiles and methods of use thereof.
    Type: Application
    Filed: September 1, 2017
    Publication date: March 8, 2018
    Inventors: Handan Acar, James LaBelle, Matthew Tirrell
  • Publication number: 20110081293
    Abstract: Disclosed are compositions and methods related to clot-binding head groups. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.
    Type: Application
    Filed: September 30, 2010
    Publication date: April 7, 2011
    Applicants: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: ERKKI RUOSLAHTI, DAVID PETERS, MATTHEW TIRRELL, MARK KASTANTIN